BIOMAT Database Logo BIOMAT Database Logo

Diagnostic accuracy of insulin-like growth factor binding protein-1 for amniotic fluid embolism*. 2012

Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Department of Anesthesiology and Critical Care, Lariboisière Hospital, Assistance Publique- Hôpitaux de Paris, EA-3509 University of Paris 7 Denis Diderot, Paris, France. matthieu.m.legrand@gmail.com

OBJECTIVE To test whether serum insulin-like growth factor binding protein-1 could be used as a biomarker of amniotic fluid passage into the maternal circulation. METHODS Case-control study. METHODS Thirteen centers in France. METHODS This case-control study included a group with amniotic fluid embolism (the amniotic fluid embolism group) and a group with symptoms unrelated to amniotic fluid embolism (the non-amniotic fluid embolism group). Serum insulin-like growth factor binding protein-1 level was measured within 6 hrs from onset of symptoms. We also determined serum insulin-like growth factor binding protein-1 in four additional groups of patients with 1) postpartum hemorrhage, 2) uncomplicated labor, 3) normal pregnancy, and 4) non-pregnant patients with acute pulmonary embolism. METHODS None. METHODS Serum insulin-like growth factor binding protein-1 levels were determined using an immuno-enzymatic assay. RESULTS The amniotic fluid embolism group included 25 patients, the non-amniotic fluid embolism group had 20 patients, the postpartum hemorrhage group had 24 patients, and the uncomplicated labor group had 50 patients. The serum levels of insulin-like growth factor binding protein-1 were higher in the amniotic fluid embolism group (234 134-635 µmol/L) compared with the non-amniotic fluid embolism, postpartum hemorrhage, and uncomplicated labor groups, which had serum levels of 56 36-91 µmol/L, 65 39-91 µmol/L and 49 30-78 µmol/L, respectively (p < .001). Serum insulin-like growth factor binding protein-1 level was not different in women during normal pregnancy (57 37-85 µg/L) compared to the uncomplicated labor group. Patients with acute pulmonary embolism had the lowest insulin-like growth factor binding protein-1 level (5 2-14 µg/L). The area under the receiver-operating-characteristic curve for serum insulin-like growth factor binding protein-1 was 0.98 0.97-1.00 for the amniotic fluid embolism diagnostic. Insulin-like growth factor binding protein-1 rose from 56 43-90 µg/L before symptoms to 458 161-1514 µg/L after the onset of symptoms in ten patients with available measurements of baseline serum insulin-like growth factor binding protein-1. CONCLUSIONS Increased serum levels of insulin-like growth factor binding protein-1 appear to be a valuable biomarker of amniotic fluid passage into the maternal circulation and may be used to diagnose amniotic fluid embolism.

UI MeSH Term Description Entries
D007743 Labor, Obstetric The repetitive uterine contraction during childbirth which is associated with the progressive dilation of the uterine cervix (CERVIX UTERI). Successful labor results in the expulsion of the FETUS and PLACENTA. Obstetric labor can be spontaneous or induced (LABOR, INDUCED). Obstetric Labor
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D004619 Embolism, Amniotic Fluid Blocking of maternal circulation by AMNIOTIC FLUID that is forced into uterine VEINS by strong UTERINE CONTRACTION near the end of pregnancy. It is characterized by the sudden onset of severe respiratory distress and HYPOTENSION that can lead to maternal DEATH. Amniotic Fluid Embolism,Amniotic Fluid Embolisms,Embolisms, Amniotic Fluid
D005260 Female Females
D006473 Postpartum Hemorrhage Excess blood loss from uterine bleeding associated with OBSTETRIC LABOR or CHILDBIRTH. It is defined as blood loss greater than 500 ml or of the amount that adversely affects the maternal physiology, such as BLOOD PRESSURE and HEMATOCRIT. Postpartum hemorrhage is divided into two categories, immediate (within first 24 hours after birth) or delayed (after 24 hours postpartum). Hemorrhage, Postpartum,Delayed Postpartum Hemorrhage,Immediate Postpartum Hemorrhage,Hemorrhage, Delayed Postpartum,Hemorrhage, Immediate Postpartum,Postpartum Hemorrhage, Delayed,Postpartum Hemorrhage, Immediate
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D018970 Insulin-Like Growth Factor Binding Protein 1 One of the six homologous proteins that specifically bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits IGF binding to cell surface receptors and thereby inhibits IGF-mediated mitogenic and cell metabolic actions. (Proc Soc Exp Biol Med 1993;204(1):4-29) IGF-Binding Protein 1,IGFBP-1,IGF Binding Protein 1,Insulin Like Growth Factor Binding Protein 1

Related Publications

Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Use of insulin-like growth factor binding protein-1 for retrospective diagnosis of amniotic fluid embolism in first trimester.
February 2014, Archives of gynecology and obstetrics,
Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Insulin-like growth factor binding protein-1, a quick way to detect amniotic fluid.
March 1998, Acta obstetricia et gynecologica Scandinavica,
Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Characterization of insulin-like growth factor-binding protein in ovine amniotic fluid.
November 1990, The Journal of endocrinology,
Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Insulin-like growth factor binding protein 1 level in amniotic fluid: correlation with birth weight.
January 1998, Biology of the neonate,
Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Evidence supporting proteolytic cleavage of insulin-like growth factor binding protein-1 (IGFBP-1) protein in amniotic fluid.
January 2008, Journal of perinatal medicine,
Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Elevated second-trimester amniotic fluid concentration of insulin-like growth factor binding protein-1 in fetal growth retardation.
July 1993, American journal of obstetrics and gynecology,
Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Contribution of blood detection of insulin-like growth factor binding protein-1 for the diagnosis of amniotic-fluid embolism: a retrospective multicentre cohort study.
November 2021, BJOG : an international journal of obstetrics and gynaecology,
Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Diagnostic accuracy of serum insulin-like growth factor-binding protein 2 for ovarian cancer.
November 2020, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Somatomedin-1 binding protein-3: insulin-like growth factor-1 binding protein-3, insulin-like growth factor-1 carrier protein.
January 2003, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Matthieu Legrand, and Mathias Rossignol, and Sophie Dreux, and Dominique Luton, and Chloé Ventré, and Emmanuel Barranger, and Said Laribi, and Didier Payen, and Françoise Muller
Proteolysis of insulin-like growth factor binding protein-5 by pregnancy serum and amniotic fluid.
April 1994, Endocrinology,
Copied contents to your clipboard!